Aromatase Inhibitors in Breast Cancer: An Update

Diana E. Lake, MD, Clifford Hudis, MD


Cancer Control. 2002;9(6) 

In This Article


The modern selective aromatase inhibitors clearly represent an important clinical advance for post-menopausal women with breast cancer. They offer greater or equal activity than tamoxifen in a variety of settings including first-and second-line treatment of metastatic disease as well as in the adjuvant setting, and they may also offer advantages in prevention. These benefits are coupled with, at least thus far, equal or lesser toxicities in most cases. Therefore, they have assumed an important role in optimal management of postmenopausal patients with hormone-responsive metastases and have an evolving role in the adjuvant setting. Teasing out the optimal means of incorporating

these agents, their potential combined with ovarian ablation for younger women, and the potential differences among them, will require active participation in the many appropriate and ongoing studies. At the same time, it is perhaps humbling to consider that more than a century after the first demonstration by George Beat-son in 1896 that hormones have an impact on the natural history of breast cancer, we are still actively studying this area of treatment.

The print version of this article was originally certified for CME credit. For accreditation details, contact: H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL 33612. Telephone: (813) 632-1349. Fax: (813) 903-4950. Email: URL:


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.